$164.8m market cap
$4.01 last close
VolitionRx is a life sciences company developing novel, simple-to-use, blood-based tests to diagnose a broad range of cancers and other conditions by identifying and measuring nucleosomes in the blood stream. The primary focus is to develop the Nu.Q family of blood-based diagnostics tests for colorectal cancer.
Investment summary
VolitionRx’s proprietary Nu.Q technology detects the level and structure of nucleosomes in the blood using one drop of blood. It is currently focused on colorectal (CRC) and lung cancers based on the most recent published proof of concept data from studies with clinical-grade Nu.Q assays. Following the proof of concept data, Volition together with the National Taiwan University will conduct a large-scale lung cancer study. During its recent capital markets day, Volition also provided more details about the most recent expansion into veterinary space (MoU signed with the Texas A&M University) and development of the so-called Nu.Q Capture technology, which investigates the use of Nu.Q to purify or enrich tumour-associated nucleosomes. As of end-Q219, Volition has $18.5m in cash, and post-period has benefited from the exercise of warrants totaling $4.8m.
Y/E Dec |
Revenue (US$m) |
EBITDA (US$m) |
PBT (US$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 0.0 | (15.0) | (15.1) | (57.29) | N/A | N/A |
| 2018A | 0.0 | (17.9) | (18.0) | (48.67) | N/A | N/A |
| 2019E | 0.1 | (18.2) | (18.3) | (46.40) | N/A | N/A |
| 2020E | 0.1 | (19.6) | (19.7) | (47.94) | N/A | N/A |
| Last updated on 13/09/2019 | ||||||
Industry outlook
The blood-based cancer screening market is in its nascent stages with great potential and serves an unmet medical need. Currently there are few, if any, non-invasive screening methods for the vast majority of cancers.
Last updated on 13/09/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (US$m) | 7.7 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Cameron Reynolds | CEO |
| David Vanston | CFO |
| Jake Micallef | Chief Scientific Officer |
| Scott Powell | Director of IR |
